← United States · All US Insider Profiles

US INSIDER PROFILE · NON-SCORING RESEARCH

TRAVERSA SERGIO

Chief Executive Officer | Officer

Identity: SEC reporting-owner CIK · Reporting-owner CIK: 0001565832

Purchase history

Companies traded
1
Purchases · 12M
3
Purchases · 24M
5
Average purchase
$378.8K
Median purchase
$178.1K
Gross purchase value
$1.9M

Companies: RELMADA THERAPEUTICS, INC.

5 SEC accession(s) · 0 joint-owner event(s). Values are reported Form 4 transaction values in USD.

Qualifying purchase disclosures

PublishedCompanyTickerRoleReported valueSEC source
2026-09-11RELMADA THERAPEUTICS, INC.RLMDChief Executive Officer | Officer$828.0KOpen filing
2025-12-16RELMADA THERAPEUTICS, INC.RLMDChief Executive Officer | Officer$113.3KOpen filing
2025-11-06RELMADA THERAPEUTICS, INC.RLMDChief Executive Officer | Officer$599.5KOpen filing
2025-08-28RELMADA THERAPEUTICS, INC.RLMDChief Executive Officer | Officer$178.1KOpen filing
2025-05-20RELMADA THERAPEUTICS, INC.RLMDChief Executive Officer | Officer$175.2KOpen filing

Post-purchase outcomes

Excess return = stock return − S&P 500 ETF (SPY adjusted close) return. Returns start on the first shared trading session on or after publication.

No completed point-in-time price outcome is available yet.

Research patterns

First purchase in 12M
0/4
Large purchase ≥ $100k
5/5
Cluster buying · 15D
4/5
Buying the dip
0/—

Routine / opportunistic: Not classifiable. These labels never affect the score or ranking.

Small samples remain visible but are not scored. This research enrichment never affects US-v1.1.